DIAGNOSIS AND MANAGEMENT OF OSTEONECROSIS OF THE JAW: A SYSTEMATIC REVIEW AND INTERNATIONAL CONSENSUS

  1. Inicio
  2. »
  3. Sin categoría
  4. »
  5. DIAGNOSIS AND MANAGEMENT OF OSTEONECROSIS OF THE JAW: A SYSTEMATIC...

J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405.

Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those patients at high risk for the development of ONJ, including cancer patients receiving high-dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage. Management of ONJ is based on the stage of the disease, size of the lesions, and the presence of contributing drug therapy and comorbidity. Conservative therapy includes topical antibiotic oral rinses and systemic antibiotic therapy. Localized surgical debridement is indicated in advanced non responsive disease and has been successful. Early data have suggested enhanced osseous wound healing with teriparatide in those without contraindications for its use. Experimental therapy includes bone marrow stem cell intralesional transplantation, low-level laser therapy, local platelet-derived growth factor application, hyperbaric oxygen, and tissue grafting.

Autor: Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F,ET AL.
Patrocinadores de la web
Lilly
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Meiji Pharma
Faes Farma